Recent progress of aptamer inhibitors targeting c-Met / 中国生化药物杂志

c-Met is one member of the receptor tyrosine kinases (RTKs).It is closely related between the over-expression of c-Met and a wide variety of tumor occurrence, development, invasion, metastasis, prognosis and drug resistance.Therefore, c-Met is a potential target for oncotherapy, and researches on its inhibitors have become a hot spot in the field of tumor treatment.Aptamers targeting c-Met are gained from systematic evolution of ligands by exponential enrichment (SELEX).They can bind to c-Met with high specificity and affinity, resulting in the activation or inhibition of c-Met.We envision that anti-c-Met aptamers would be ideal new c-Met inhibitors after optimization, and could be developed into potential targeted drugs for cancers.

New research progresses on the prostate apoptosis response protein-4 for apoptosis induction cancer and its mechanism / 中国生化药物杂志

Prostate apoptosis response gene-4(par-4)was first identified from the prostate tissue.This gene can express in both normal and cancer cells.The translation product of par-4 is prostate apoptosis response protein-4 ( Par-4 ) , which is unique in its ability to selectively induce apoptosis in cancer cells while leaving the normal cells unaffected through intracellular and extracellular pathway.Par-4 is cleaved and phosphorylated by caspase3 and PKA; Par-4 transportsFas/FasL tocell membrane and activation of pro-apoptotic pathway;intracellular Par-4 transports GPR78 to cell membrane;extracellular Par-4 binds to GRP78 and activates it.There is a significant potential role in anti-tumors therapy of extracellular Par-4.The latest research progress on the mechanism of apoptosis induced by Par-4 and the treatment of exogenous Par-4 in tumor was discussed in this article.